Item Type | Name |
Concept
|
Chemotherapy, Adjuvant
|
Academic Article
|
Sentinel node biopsy prior to neoadjuvant chemotherapy.
|
Academic Article
|
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
|
Academic Article
|
Invasive breast cancer.
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
Academic Article
|
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
|
Academic Article
|
HER2 and response to paclitaxel in node-positive breast cancer.
|
Academic Article
|
Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
|
Academic Article
|
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
|
Academic Article
|
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
|
Academic Article
|
Indications for prognostic gene expression profiling in early breast cancer.
|
Academic Article
|
From genome to bedside: are we lost in translation?
|
Academic Article
|
CYP2D6 testing for breast cancer patients: is there more to the story?
|
Academic Article
|
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
|
Academic Article
|
Pretreatment worry and neurocognitive responses in women with breast cancer.
|
Academic Article
|
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
|
Academic Article
|
Markers of increased risk for failure of adjuvant therapies.
|
Academic Article
|
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
|
Academic Article
|
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
|
Academic Article
|
Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
|
Academic Article
|
Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.
|
Academic Article
|
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
|
Academic Article
|
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
|
Academic Article
|
Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
|
Academic Article
|
Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
|
Academic Article
|
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
|
Academic Article
|
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
|
Academic Article
|
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
|
Academic Article
|
Tamoxifen: Dr. Jekyll and Mr. Hyde?
|
Academic Article
|
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.
|
Academic Article
|
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
|
Academic Article
|
Disease related indicators for a proper choice of adjuvant treatments.
|
Academic Article
|
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
|
Academic Article
|
Breast-Cancer Recurrence after Stopping Endocrine Therapy.
|
Academic Article
|
Factors influencing the use of extended adjuvant endocrine therapy.
|
Academic Article
|
Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.
|
Academic Article
|
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
|
Academic Article
|
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
|
Academic Article
|
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
|
Academic Article
|
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
|
Academic Article
|
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
|
Academic Article
|
Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis.
|
Academic Article
|
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
|
Academic Article
|
Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation.
|
Academic Article
|
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
|
Academic Article
|
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
|
Academic Article
|
Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?
|
Academic Article
|
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
|
Academic Article
|
Targeting adjuvant chemotherapy: a good idea that needs to be proven!
|
Academic Article
|
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
|
Academic Article
|
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
|